期刊文献+

GLP-1类似物的葡萄糖浓度依赖性降糖机制研究

Mechanism of GLP-1 analogue on glucose-dependent hypoglycemic effect
下载PDF
导出
摘要 目的探讨胰高糖素样肽-1(GLP-1)类似物(Exendin-4)对MIN6细胞的葡萄糖浓度依赖性降糖作用机制。方法检测GLP-1类似物(Exendin-4)在不同葡萄糖浓度下对体外培养的MIN6细胞的ATP水平、cAMP含量、腺苷酸环化酶活性和胰岛素分泌量的变化。结果在2.8 mmol/L葡萄糖培养条件下,Ex-endin-4使细胞三磷酸腺苷(ATP)水平无明显变化,环磷酸腺苷(cAMP)含量、腺苷酸环化酶活性和胰岛素分泌量无明显增加(P>0.05);在25 mmol/L葡萄糖培养条件下,Exendin-4使细胞ATP水平明显降低,cAMP含量、腺苷酸环化酶活性和胰岛素分泌量明显增加(P<0.05)。结论 GLP-1类似物(Exendin-4)具有葡萄糖浓度依赖的促胰岛素分泌作用,细胞内cAMP含量增加是其引起胰岛素释放的关键环节。 Objective】To explore the glucose-dependent hypoglycemic mechanism by which glucagon-like peptide-1(GLP-1) analogue stimulates insulin secretion in MIN6 cells.【Methods】We detected cAMP content,ATP level and the amount of insulin secretion in cultured MIN6 cells which were incubated with GLP-1 analogue(Exendin-4) in different glucose concentration.【Results】In the presence of 2.8 mmol/L glucose,exendin-4 could not increase cAMP content and insulin secretion in cells,and ATP level showed insignificant change(P〈 0.05).In the presence of 25 mmol/L glucose,exendin-4 produced marked increase of insulin secretion and cAMP content,together with decreased ATP level(P〈 0.05).【Conclusion】Exendin-4 stimulates the glucose-dependent production of cAMP.Elevated cAMP in β cells plays the key role in inducing insulin secretion.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2013年第15期15-18,共4页 China Journal of Modern Medicine
关键词 胰高糖素样肽-1类似物 三磷酸腺苷 环磷酸腺苷 腺苷酸环化酶 胰岛素 glucagon-like peptide-1 analogue ATP cAMP adenylate cyclase insulin
  • 相关文献

参考文献15

  • 1CERNEA S, RAZ I. Therapy in the early stage: incretins[J]. Diabetes Care, 2011, 34 Suppl 2: S264-271.
  • 2KJEMS LL, HOLST JJ, OLUND A, et ak The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects[J]. Diabetes, 2003, 52(2): 380-386.
  • 3GUAN N, GAO W, HE M, et al. Dynamic monitoring of [3 -cell injury with impedance and rescue by glucagon-like peptide-1 [J]. Anal Biochem, 2012, 423(1): 61-69.
  • 4D'AMICO E, HUI H, KHOURY N, et al. Pancreatic beta-cells ex- pressing GLP-I are resistant to the toxic effects of immunosuppressive drugs[J]. J Mol Endocrinol, 2005, 34(2): 377-390.
  • 5DEFRONZO RA, ABDUL-GHANI MA. Preservation of 13 -cell func- tion: the key to diabetes prevention[J]. J Clin Endoerinol Metab, 2011, 96(8): 2354-2366.
  • 6BLEVINS T. Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes [J]. Postgrad Med, 2010, 122(1): 172-183.
  • 7SALEHI M, VAHL TP, D'ALESSIO DA. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion [J]. J Clin Endocrinol Metab, 2008, 93 (12): 4909-4916.
  • 8CHAI W, DONG Z, WANG N, et al. Glueagon-like peptide 1 recruits micmvaseulature and increases glucose use in muscle via a nitric ox- ide-dependent mechanism[J]. Diabetes, 2012, 61(4): 888-896.
  • 9DEACON CF, MARX N. Potential cardiovascular effects of in- cretin-based therapies[J]. Expert Rev Cardiovasc Ther, 2012, 10(3): 337-351.
  • 10SPELLMAN CW. Incorporating glucagon-like peptide-1 receptor ag- onists into clinical practice[J]. J Am Osteopath Assoc, 2012, 112(1 Suppl 1): $7-15.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部